Chemistry:ABT-925
ABT-925, also known as A-437203 or as LU-201640, is a selective dopamine D3 receptor antagonist which was under development for the treatment of schizophrenia but was never marketed.[1][2][3] It is taken orally.[1][3]
The drug shows affinity for the dopamine D3 receptor and to a much lesser extent for the dopamine D2 receptor, with Ki values of 0.97–3.2 nM and 75 nM, respectively, and with 45- to 120-fold selectivity for the dopamine D3 receptor over the dopamine D2 receptor.[4][5][3] It showed little activity in classical tests of antipsychotic-like activity in rodents, for instance inhibition of methamphetamine-induced hyperlocomotion and inhibition of apomorphine-induced climbing behavior.[5][6] The drug does not produce catalepsy and does not affect prolactin levels in rodents.[5][6] The occupancy of the dopamine D3 receptor by ABT-925 has been studied in humans.[4][7][8]
ABT-925 was first described in the scientific literature by 1997.[5][9][6] At the time, it was the most potent and selective dopamine D3 receptor antagonist yet known.[5] In addition, the drug has been said to have been the first selective dopamine D3 receptor antagonist.[4] It was under development by Abbott Laboratories.[1][2] The drug reached phase 2 clinical trials prior to the discontinuation of its development.[1][2] ABT-925 is known to have been in active phase 2 trials between 2001 and 2007.[1] It failed to show antipsychotic effectiveness in acute schizophrenia in a phase 2 trial published in 2011.[10][4][3]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "ABT 925". 24 January 2013. https://adisinsight.springer.com/drugs/800012940.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on A-437203 with Synapse". 30 May 2026. https://synapse.patsnap.com/drug/932eb810ee2c4ad58a24fc08a2e495f1.
- ↑ 3.0 3.1 3.2 3.3 "A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia". Journal of Clinical Psychopharmacology 31 (2): 221–225. April 2011. doi:10.1097/JCP.0b013e31820e4818. PMID 21346607.
- ↑ 4.0 4.1 4.2 4.3 "Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia". Naunyn-Schmiedeberg's Archives of Pharmacology 386 (2): 155–166. February 2013. doi:10.1007/s00210-012-0806-3. PMID 23128852.
- ↑ 5.0 5.1 5.2 5.3 5.4 "S. 21.02 Evaluation of D3 receptor antagonists". European Neuropsychopharmacology 7: S120. 1997. doi:10.1016/S0924-977X(97)88428-3. https://scholar.google.com/scholar?cluster=9631558256460925716.
- ↑ 6.0 6.1 6.2 "In vivo effects of the selective dopamine D3 receptor antagonist A-437203". Abstr.-Soc. Neurosci. 28. November 2002. https://www.sfn.org/meetings/past-and-future-sfn-meetings/abstract-archive/Abstract-Archive-Details?AbsYear=2002&AbsID=13405.
- ↑ "Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925". The International Journal of Neuropsychopharmacology 13 (3): 273–287. April 2010. doi:10.1017/S1461145709990642. PMID 19751545.
- ↑ "D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET". The International Journal of Neuropsychopharmacology 13 (3): 291–292. April 2010. doi:10.1017/S1461145710000180. PMID 20196920.
- ↑ "In vitro characterization of the selective dopamine D3 receptor antagonist A-437203". Abstr.-Soc. Neurosci. 28. 2002. https://www.sfn.org/meetings/past-and-future-sfn-meetings/abstract-archive/Abstract-Archive-Details?AbsYear=2002&AbsID=13404.
- ↑ "Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs". European Neuropsychopharmacology 25 (9): 1437–1447. September 2015. doi:10.1016/j.euroneuro.2015.07.012. PMID 26298833.
